Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318783 · ClinicalTrials.gov registry record · Phase 1
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03318783 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 20 participants.
The verdict
NCT03318783, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH enzyme is safe and will result in increased EETs availability in the blood and cerebrospinal fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to evaluate the safety and efficacy of GSK2256294, a novel soluble epoxide hydrolase inhibitor in patients with aneurysmal SAH.
Interventions
- DRUG Placebo
- DRUG GSK2256294
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318783
The ClinicalTrials.gov registry entry for NCT03318783 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03318783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318783 about?
NCT03318783 is a clinical study titled "Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial". Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids (EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH enzyme is safe and will result i...
What is the current status of trial NCT03318783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-05-02. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT03318783?
The interventions under investigation include: Placebo (DRUG), GSK2256294 (DRUG).
Who is sponsoring clinical trial NCT03318783?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.